LeonaBio Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
LONA
- Investments
-
1
- Share Price
-
$2.60
- (As of Wednesday Closing)
LeonaBio General Information
Description
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Contact Information
Website
www.leonabio.comCorporate Office
- 18706 North Creek Parkway
- Suite 104
- Bothell, WA 98011
- United States
Corporate Office
- 18706 North Creek Parkway
- Suite 104
- Bothell, WA 98011
- United States
LeonaBio Stock Performance
As of 18-Nov-2026, LeonaBio’s stock price is $2.60. Its current market cap is $34.7M with 13.1M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.60 | $2.76 | $2.21 - $14.21 | $34.7M | 13.1M | 193K | -$22.20 |
LeonaBio Financials Summary
As of 30-Sep-2026, LeonaBio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (16,855) | 46,090 | (44,855) | (78,803) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (155,087) | (104,637) | (95,970) | (116,703) |
| Net Income | (156,008) | (105,609) | (96,940) | (117,672) |
| Total Assets | 38,136 | 92,151 | 58,779 | 160,245 |
| Total Debt | 460 | 803 | 1,217 | 1,585 |
LeonaBio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LeonaBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
LeonaBio Comparisons
Industry
Financing
Details
LeonaBio Competitors (14)
One of LeonaBio’s 14 competitors is Filana Therapeutics, a Formerly VC-backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Filana Therapeutics | Formerly VC-backed | Austin, TX | ||||
| ZyVersa Therapeutics | Formerly VC-backed | Lighthouse Point, FL | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France |
LeonaBio Patents
LeonaBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026060341-A1 | Modulators of pannexin-1 activity | Pending | 16-Sep-2024 | ||
| WO-2025189066-A1 | Modulators of g protein-coupled receptor 55 (gpr55) | Pending | 08-Mar-2024 | ||
| WO-2025189066-A8 | Modulators of g protein-coupled receptor 55 (gpr55) | Pending | 08-Mar-2024 | ||
| JP-2025538382-A | Methods for treating inflammatory conditions | Pending | 18-Nov-2022 | ||
| AU-2023383348-A1 | Methods of treating inflammatory conditions | Pending | 18-Nov-2022 | A61K31/519 |
LeonaBio Signals
LeonaBio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
LeonaBio Investments (1)
LeonaBio’s most recent deal was a Corporate Asset Purchase with Sermonix Pharmaceuticals (Rights for the Development and Commercialization of Lasofoxifene). The deal was made on 18-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sermonix Pharmaceuticals (Rights for the Development and Commercialization of Lasofoxifene) | 18-Dec-2025 | Corporate Asset Purchase | Buildings and Property |
LeonaBio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.32 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
LeonaBio FAQs
-
When was LeonaBio founded?
LeonaBio was founded in 2011.
-
Where is LeonaBio headquartered?
LeonaBio is headquartered in Bothell, WA.
-
What is the size of LeonaBio?
LeonaBio has 19 total employees.
-
What industry is LeonaBio in?
LeonaBio’s primary industry is Drug Discovery.
-
Is LeonaBio a private or public company?
LeonaBio is a Public company.
-
What is LeonaBio’s stock symbol?
The ticker symbol for LeonaBio is LONA.
-
What is the current stock price of LeonaBio?
As of 18-Nov-2026 the stock price of LeonaBio is $2.60.
-
What is the current market cap of LeonaBio?
The current market capitalization of LeonaBio is $34.7M.
-
Who are LeonaBio’s competitors?
Filana Therapeutics, ZyVersa Therapeutics, Alzheon, Alector, and AB Science are some of the 14 competitors of LeonaBio.
-
What is LeonaBio’s annual earnings per share (EPS)?
LeonaBio’s EPS for 12 months was -$22.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process